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Disclaimer 
• The views and opinions expressed in this 
presentation belong to me and do not represent 
official FDA policy. 
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Outline 
• Evolution of analytical tool box 
– Mass Spec 
– CE 
 
• State-of-the-Art analytical methods through the product 
lifecycle 
– Expectations 
 
• FDA’s Emerging Technology Program 
– Small molecule examples 
– Potential application to and challenges for biotech products 
 
• Take home messages 
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1990s Analytical Tool Box 
1o Sequence/PTMs 
AA analysis 
N- and C-term Sequence 
Peptide Mapping and Sequencing 
LC-MS/MS (1 sponsor) 
MALDI-TOF (BLA) 
ESI-MS (BLA) 
 
  HOS 
CD (1 sponsor) 
DSC (BLA) 
    
Glycan Analysis 
Monosaccharide analysis 
CE with fluorescence detection (BLA) 
Charge/Identity 
IEF 
IEX 
cIEF 
 
Size/ Purity 
SEC-HPLC 
SDS-PAGE R + NR 
   Coomassie Blue and 
   Silver Stain 
Immunoblotting 
CGE (BLA) 
Activity 
In vitro/ in vivo Bioassays 
Binding ELISAs 
Flow cytometry 
Strength (UV A280) 
BCA (1 DS) 
Safety 
Bioburden 
Sterility 
Rabbit Pyrogens 
Endotoxin 
General Safety 
Japelj et al Sci Reports 2016 
Process Related Impurities 
Largely focused on bovine proteins 
  BSA, transferrin, IgG 
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2000s Analytical Tool Box 
1o Sequence/PTMs 
AA analysis 
N- and C-term Sequence 
Peptide Mapping and Sequencing 
   LC-MS/MS 
MALDI-TOF 
ESI- MS 
QTOF 
Ion trap 
 
  HOS 
CD 
Fluorescence spec 
    
Glycan Analysis 
Monosaccharide analysis 
2-AB Labeled, PNGaseF released 
NP-HPLC 
CE-LIF 
  
    Charge 
IEF 
IEX- HPLC 
CEX 
cIEF 
 
Size/ Purity 
SEC-HPLC 
SDS-PAGE R + NR 
   Coomassie Blue and 
   Silver Stain 
Immunoblotting 
CE-SDS/CGE 
Activity 
In vitro Bioassays 
Ag/Receptor Binding assays 
Flow cytometry 
SPR 
Strength (UV A280) 
Safety 
Bioburden 
Sterility 
Endotoxin 
   LAL 
Japelj et al Sci Reports 2016 
Process Related Impurities 
DNA, HCP, Protein A, etc. 
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The Current Analytical Tool Box 
1o Sequence/PTMs 
AA analysis 
N- and C-term Sequence 
Peptide Mapping and Sequencing 
   LC-MS/MS 
Free sulfhydryls 
MALDI-TOF, ESI-QTOF-MS,  orbitrap, 
etc…. 
HOS 
Near- and Far-UV CD 
FTIR 
DSC 
HDX-MS 
X-ray 
NMR 
    
Glycan Analysis 
ESI- MS 
MALDI-TOF MS 
Labeled, PNGaseF released 
   HPAEC-PAD 
   HPLC-FD 
   HILIC (HPLC, UHPLC) 
   UPHPLC 
   CE-LIF (MS) 
  
    
Charge 
cIEF 
icIEF 
ICE 
IEX- HPLC 
CZE 
Size/ Purity 
SEC-HPLC 
HIC-HPLC 
CE-SDS 
CGE 
AUC 
A4F 
Activity 
In vitro Bioassays 
   Reporter gene assays 
Ag/Receptor Binding assays 
   (mAbs – FcR, C1q) 
SPR 
Strength (UV A280) 
Safety 
Bioburden 
Sterility 
Endotoxin 
   LAL 
   KT 
Japelj et al Sci Reports 2016 Process Related Impurities 
DNA, HCP, Protein A, etc. 
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A Retrospective Evaluation of the Use of Mass 
Spectrometry in FDA Biologics License Applications 
• 79/80 electronic submission BLA between 2000 and 
2015 used MS for characterization 
– mAbs, ADCs, fusion-proteins, other proteins 
 
• 32 specific attributes were analyzed 
 
• Trends were noted for MS work flows, methods, 
instrumentation, and attributes analyzed over time 
 
• “…we expect that we will see additional MS 
methodology within the quality control and 
comparability sections.” 
Rogstad, S. et al., J. Am. Soc. Mass Spectrom. (2016) 
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Introduction of MS Instruments and Scan 
Types Over Time 
Rogstad, S. et al., J. Am. Soc. Mass Spectrom. (2016) 
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Major MS Attributes for Analysis 
Rogstad, S. et al., J. Am. Soc. Mass Spectrom. (2016) 
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It Takes Time for New Methods to be Used 
Routinely for  QC  
• Although we saw some CE based methods for 
release/stability in the late 1990s, they became 
“routine” in the past 5-10 years 
 
• CE method(s) are included in the specs for:  
– 35% of products through 2009  
– 44% of products through October 2014  
• 58% of products approved in the 5 years prior to the 2014 
meeting 
– 52% of products up to September 2016 
• 90% of products approved in the 2 years since the 2014 
meeting 
 
Source: Sarah Kennett  CASSS CE Pharm meeting 
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State-of-the-Art Analytical Methods Throughout the 
Product Lifecycle 
Research Clinical Development Commercial 
R&D Pre-clinical Phase 1 Phase 2 Phase 3 Comparability 
Analytical Method Lifecycle 
High throughput methods, NGS,  
MAM, metabolomics, PCA for 
• Candidate Selection 
• Cell line development 
• Process Development 
Regulatory expectations 
• Characterization (SotA) 
• Robust methods for release 
and stability 
• Update methods and panel 
of methods as appropriate 
for release, stability, 
characterization and 
comparability 
 
Regulatory expectations 
• Characterization (SotA) 
• Robust methods for release 
and stability 
• Update methods and panel 
of methods as appropriate 
• OK if updated methods find 
new things that were 
always there, resulting in a 
change in specs 
 
Impact of Biosimilars 
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Quality Considerations in Demonstrating Biosimilarity of 
a Therapeutic Protein Product to a Reference Product  
• Sponsors should use appropriate analytical methodology that has adequate 
sensitivity and specificity to detect and characterize differences between the 
proposed product and the reference product. Accordingly, FDA encourages 
the use of widely available state-of-the-art technology. 
 
• A meaningful assessment as to whether the proposed product is highly 
similar to the reference product depends on, among other things, the 
capabilities of available state-of-the-art analytical assays to assess, for 
example, the molecular weight of the protein, complexity of the protein 
(higher order structure and posttranslational modifications), degree of 
heterogeneity, functional properties, impurity profiles, and degradation 
profiles denoting stability. The capability of the methods used in these 
analytical assessments, as well as their limitations, should be described by 
the sponsor. 
 
• Current analytical technology is capable of evaluating the three-dimensional 
structure of many proteins. Using multiple, relevant, state-of-the-art 
methods can help define tertiary protein structure and, to varying extents, 
quaternary structure and can add to the body of information supporting 
biosimilarity. 
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2D NMR of Filgrastim  
US- licensed Neupogen batch (orange) and one ZARXIO batch (blue) 
Figure from Sandoz ODAC briefing package 1/7/2015 
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2D NMR of NIST mAb 
Intact 
mAb Fab + Fc 
Fab 
Fragment 
Fc 
fragment 
Arbogast et al. Analytical Chemistry  87: 3556, 2015 
Could be used for comparability – but is it value added? 
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It Depends….. 
Methods seen more often in 
biosimilar packages 
Mostly HOS methods 
• HDX-MS 
• NMR (1D and 2D) 
• X-ray crystallography 
 
Multiple MOA methods 
• Some MOAs may not have 
been known or understood at 
the time the reference product 
was licensed, or good methods 
were not available. 
 
Many methods are standard 
across sponsors 
• Capillary based methods (size and 
charge) 
• Multiple MS methods for sequencing, 
PTM identification/quantitation, 
glycan analysis 
• Glycan profiling 
• Other HOS methods (CD, FTIR, DSC) 
• Size methods (SEC, AUC, SEC-MALLS) 
• SVP analysis (HIAC, MFI, Archimedes)  
• Methods that assess biological 
function 
– Bioassays 
– Immunochemical/biochemical assays 
– Binding assays 
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State of the Art Methods 
• Used first as characterization methods 
– Are not validated, but fit for purpose 
– May not be readily transferable and may require specialists 
– As seen for capillary based methods, it took a while for routine use 
in QC labs 
 
• MS methods may not be practical for QC 
– New methods and instruments introduced often 
– Need an instrument and software that vendor will support for 
many years 
 
• Which HOS methods are best suited for comparability and/or 
analytical similarity of mAbs? 
– Can you tell one IgG1 apart from another? 
 
• But could be invaluable for understanding the process and 
product during development 
– Fit for purpose 
17 
Emerging Technology Draft Guidance (2015) 
• Modernizing manufacturing technology may lead to a 
more robust manufacturing process with fewer 
interruptions in production, fewer product failures 
(before or after distribution), and greater assurance that 
the drug products manufactured in any given period of 
time will provide the expected clinical performance  
 
• Examples of such elements in a planned submission 
include an innovative or novel: (1) product manufacturing 
technology, such as the dosage form; (2) manufacturing 
process (e.g., design, scale-up, and/or commercial scale); 
and/or (3) testing technology  
 
• Will generally be unfamiliar in both industrial and 
regulatory contexts with limited or no regulatory 
precedence 
 
 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM478821.pdf 
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 FDA’s Emerging Technology Program 
• Experience with Small Molecule Drugs 
– 3-D Printed Tablet (way cool!) 
• Approved in 2015 
• Rapidly disintegrating, easy to swallow 
 
– Novel Long-Acting Oral Drug Delivery 
• Current extended and sustained release achieves therapeutic 
serum levels for 12-24 hours 
• Aim to extend this out to >1 week with 1 pill 
• Will improve adherence to medication regimens 
 
– Continuous Manufacturing 
• Approved a PAS for oral tablets 
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Contacting the Emerging Technology Team 
(ETT) 
• ETT Contact: CDER-ETT@fda.hhs.gov 
 
• Early Stage of Development: ET proposal may or 
may not be tied to a particular product or 
regulatory submission 
 
• Advanced Stage of Development: Pre-
submission meetings for regulatory applications 
with ET component (INDs, BLAs) 
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Where is Biotech Headed? 
• Multi-Attribute Methods 
–  Mass Spectrometry 
• Bottom up 
• Top down 
• Middle out 
• Continuous Manufacturing 
– Advanced Process Controls 
• PAT 
• RTRT 
• Already exist to some extent for biotech products 
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Mass Spec Based Multi-Attribute Methods 
• Mass Spec played an important role in thinking of 
therapeutic proteins as “well characterized”. 
 
• MS can be coupled with separation technologies. 
– MS can identify and quantify specific PTMs and sequence 
variants and when coupled with separation techniques, can 
tell you which peak contains the variant. 
 
But… 
 
• Can MS replace QC methods such as CE, IEX, SEC, RP-
HPLC and HIC-HPLC, which tell you about quality 
attributes of the population, but not at a molecular 
level? 
 
• Can MS be used to move release testing to in-process 
testing? 
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Considerations/Concerns   
• Some sample preparation steps can alter specific 
QAs. 
• Bottom up approaches may not be/are not 
sufficient. 
• Are you analyzing the correct attributes? 
• You’ve identified and quantified specific PTMs 
and sequence variants, but do you know if they 
are evenly distributed across molecules or only 
on 10% of the population? 
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Considerations/Concerns   
• If the PTM has the potential to affect potency or activity, does knowing 
the overall level tell you what you need to know? 
– For example, if CDRs of a mAb may be prone to 2 PTMs, is one PTM 
sufficient to reduce potency or would both PTMs be needed, on one or both 
halves of the molecule ? 
– May not be able to tell you if there was an overall shift in the PI of the 
product, which could affect PK of sc administration 
– However, may be better for setting a spec around a specific PTM with a 
known impact, rather than setting a spec on an acidic or basic peak. 
 
• If you want to use MS for in-process testing instead of release testing, 
are you using it in the correct place during manufacture? 
– Can the attributes you are assessing be affected by steps downstream of 
where you are testing? 
 
• Have you performed an adequate risk assessment of the testing strategy 
on potency, PK, safety and immunogenicity? 
– Does the MAM give you the information you/we need in order to make 
appropriate decisions? 
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Continuous Manufacturing  
• Perfusion bioreactors 
– Some approved products are manufactured in perfusion 
bioreactors followed by batch downstream processes 
– Can be run at high cell densities resulting in higher productivity 
with reduced impurities in the harvest 
– Need stable cell lines and optimal media formulations that can 
produce consistent yields for prolonged periods. 
– Could minimize PTMs and degradation that are associated with 
prolonged exposure to bioreactor pH and temperature or host cell 
proteolytic enzymes. 
 
• Downstream single use process technologies 
– Some experience with continuous downstream processes 
• Not for entire downstream process 
– Challenges for multiple columns, continuous virus inactivation and 
UF/DF are being addressed. 
– Need to control bioburden over prolonged periods. 
 
Konstantinov and Cooney. White Paper. J. Pharm. Sci 104:813. 2015  
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Continuous Manufacturing – Additional 
Challenges  
• Need appropriate analytics at the right places 
 
• Need good Advanced Process Controls for in-process 
tests and assurance of virus inactivation/removal 
 
• Increased dependence on quality and consistency of 
raw materials 
 
• Greater dependency of vendors of single use 
technologies 
 
• For biotech products, the know-how exists 
– The challenges may not be regulatory 
 
 
 
Konstantinov and Cooney. White Paper. J. Pharm. Sci 104:813. 2015  
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Take Home Messages 
• Be innovative and push the envelope, but… 
 
• Don’t oversell! 
 
• Your new analytics/advanced technologies may be the 
greatest invention since sliced bread, but we need to 
come to the same conclusion (and we might not!) 
 
• Put yourself in our shoes – what would be our 
concerns? 
 
• Back up your claims with the right kind of 
    data! 
 
• Know your protein! 
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